{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:42:04Z","timestamp":1788561724742,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiac amyloidosis is a fatal disorder caused by deposition of abnormally folded protein in the interstitial space. One of the proteins most associated with the disease is transthyretin (TTR), which leads to a progressive infiltrative cardiomyopathy (CM). Previously thought to be a rare disorder, there is growing recognition of it as a common cause of heart failure in the elderly and African Americans. The application of bone scintigraphy to the diagnosis of ATTR amyloidosis now allows for accurate and non-invasive diagnosis of the disease, rather than the previously necessary tissue biopsy. Targeted pharmacotherapies have been developed in the past few years that stabilize TTR, silence genes responsible for TTR production, or remove abnormal protein deposited in tissues. As of March 2025, Vutrisiran is the latest addition to the FDA-approved medications for ATTR-CM, alongside Tafamidis and Acoramidis. Several emerging therapies, including novel drugs and promising gene editing techniques are currently under investigation. As the number of available treatments continues to grow, maintaining a high index of suspicion and timely screening for the disease using laboratory tests, electrocardiography, and imaging has become increasingly important. In addition, with advancements in artificial intelligence (AI), new methods are in development to enhance screening of patients with suspected ATTR amyloidosis. These AI-driven tools could be integrated into electronic medical record systems to flag at-risk patients and allow for more rapid diagnosis. This review provides an overview of the current landscape and future directions of the diagnosis, treatment, and screening of ATTR-CM.<\/jats:p>","DOI":"10.1007\/s10741-025-10552-9","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T23:16:46Z","timestamp":1756423006000},"page":"1341-1352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Transthyretin cardiac amyloidosis: advances and ambiguities"],"prefix":"10.1007","volume":"30","author":[{"given":"Alexandrina","family":"Danilov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"D\u2019Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enklajd","family":"Marsela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Costabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich P.","family":"Jorde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogita","family":"Rochlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"10552_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13506129.2020.1835263","volume":"27","author":"MD Benson","year":"2020","unstructured":"Benson MD, Buxbaum JN, Eisenberg DS et al (2020) Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 27:217\u2013222. https:\/\/doi.org\/10.1080\/13506129.2020.1835263","journal-title":"Amyloid"},{"key":"10552_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","volume":"12","author":"LG Gilstrap","year":"2019","unstructured":"Gilstrap LG, Dominici F, Wang Y et al (2019) Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail 12:e005407. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005407","journal-title":"Circ Heart Fail"},{"key":"10552_CR3","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","volume":"141","author":"DS Kazi","year":"2020","unstructured":"Kazi DS, Bellows BK, Baron SJ et al (2020) Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation 141:1214\u20131224. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.045093","journal-title":"Circulation"},{"key":"10552_CR4","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","volume":"74","author":"J Ternacle","year":"2019","unstructured":"Ternacle J, Krapf L, Mohty D et al (2019) Aortic Stenosis and Cardiac Amyloidosis. JACC 74:2638\u20132651. https:\/\/doi.org\/10.1016\/j.jacc.2019.09.056","journal-title":"JACC"},{"key":"10552_CR5","doi-asserted-by":"crossref","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, et al (2008) Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2\u2010macroglobulin and tau: A population\u2010based autopsy study","DOI":"10.1080\/07853890701842988"},{"key":"10552_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","volume":"75","author":"GG Cornwell","year":"1983","unstructured":"Cornwell GG, Murdoch WL, Kyle RA et al (1983) Frequency and distribution of senile cardiovascular amyloid: A clinicopathologic correlation. Am J Med 75:618\u2013623. https:\/\/doi.org\/10.1016\/0002-9343(83)90443-6","journal-title":"Am J Med"},{"key":"10552_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","volume":"68","author":"MS Maurer","year":"2016","unstructured":"Maurer MS, Hanna M, Grogan M et al (2016) Genotype and Phenotype of Transthyretin Cardiac Amyloidosis in the United States: The Transthyretin Amyloid Outcome Survey (THAOS). J Am Coll Cardiol 68:161\u2013172. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.596","journal-title":"J Am Coll Cardiol"},{"key":"10552_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/13506129.2015.1051219","volume":"22","author":"DR Jacobson","year":"2015","unstructured":"Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN (2015) Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid 22:171\u2013174. https:\/\/doi.org\/10.3109\/13506129.2015.1051219","journal-title":"Amyloid"},{"key":"10552_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/13506129.2020.1841623","volume":"28","author":"F Gorram","year":"2021","unstructured":"Gorram F, Olsson M, Alarcon F et al (2021) New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis 28:84\u201390. https:\/\/doi.org\/10.1080\/13506129.2020.1841623","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"key":"10552_CR10","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/jnnp.59.1.45","volume":"59","author":"MM Reilly","year":"1995","unstructured":"Reilly MM, Staunton H, Harding AE (1995) Familial amyloid polyneuropathy (TTR ala 60) in north west Ireland: a clinical, genetic, and epidemiological study. J Neurol Neurosurg Psychiatry 59:45\u201349. https:\/\/doi.org\/10.1136\/jnnp.59.1.45","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10552_CR11","unstructured":"Sekijima Y, Nakamura K (1993) Hereditary Transthyretin Amyloidosis. In: Adam MP, Feldman J, Mirzaa GM, et al (eds) GeneReviews\u00ae. University of Washington, Seattle, Seattle (WA)"},{"key":"10552_CR12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.ahj.2010.02.006","volume":"159","author":"J Buxbaum","year":"2010","unstructured":"Buxbaum J, Alexander A, Koziol J et al (2010) Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J 159:864\u2013870. https:\/\/doi.org\/10.1016\/j.ahj.2010.02.006","journal-title":"Am Heart J"},{"key":"10552_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.amjcard.2011.03.069","volume":"108","author":"D Jacobson","year":"2011","unstructured":"Jacobson D, Tagoe C, Schwartzbard A et al (2011) Relation of Clinical, Echocardiographic and Electrocardiographic Features of Cardiac Amyloidosis to the Presence of the Transthyretin V122I Allele in Older African-American Men. Am J Cardiol 108:440\u2013444. https:\/\/doi.org\/10.1016\/j.amjcard.2011.03.069","journal-title":"Am J Cardiol"},{"key":"10552_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028973","volume":"12","author":"A Madhani","year":"2023","unstructured":"Madhani A, Sabogal N, Massillon D et al (2023) Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN-MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study. J Am Heart Assoc 12:e028973. https:\/\/doi.org\/10.1161\/JAHA.122.028973","journal-title":"J Am Heart Assoc"},{"key":"10552_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","volume":"372","author":"CC Quarta","year":"2015","unstructured":"Quarta CC, Buxbaum JN, Shah AM et al (2015) The Amyloidogenic V122I Transthyretin Variant in Elderly Black Americans. N Engl J Med 372:21\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1404852","journal-title":"N Engl J Med"},{"key":"10552_CR16","doi-asserted-by":"publisher","first-page":"120e","DOI":"10.1136\/jmg.40.11.e120","volume":"40","author":"V Plante-Bordeneuve","year":"2003","unstructured":"Plante-Bordeneuve V (2003) Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 40:120e\u20131120. https:\/\/doi.org\/10.1136\/jmg.40.11.e120","journal-title":"J Med Genet"},{"key":"10552_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A et al (2019) Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation 140:16\u201326. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038169","journal-title":"Circulation"},{"key":"10552_CR18","doi-asserted-by":"publisher","unstructured":"Fontana M, Berk JL, Gillmore JD, et al Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med 0: https:\/\/doi.org\/10.1056\/NEJMoa2409134","DOI":"10.1056\/NEJMoa2409134"},{"key":"10552_CR19","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 133:2404\u20132412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"10552_CR20","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379:1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"10552_CR21","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F et al (2024) Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med 390:132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"},{"key":"10552_CR22","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M et al (2023) Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med 389:1553\u20131565. https:\/\/doi.org\/10.1056\/NEJMoa2300757","journal-title":"N Engl J Med"},{"key":"10552_CR23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R et al (2017) Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation 135:1357\u20131377. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024438","journal-title":"Circulation"},{"key":"10552_CR24","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV et al (2020) Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation 142:e7\u2013e22. https:\/\/doi.org\/10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"key":"10552_CR25","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","volume":"114","author":"JA Vrana","year":"2009","unstructured":"Vrana JA, Gamez JD, Madden BJ et al (2009) Classification of amyloidosis by laser microdissection and mass spectrometry\u2013based proteomic analysis in clinical biopsy specimens. Blood 114:4957\u20134959. https:\/\/doi.org\/10.1182\/blood-2009-07-230722","journal-title":"Blood"},{"key":"10552_CR26","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","volume":"1","author":"A Castano","year":"2016","unstructured":"Castano A, Haq M, Narotsky DL et al (2016) Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol 1:880\u2013889. https:\/\/doi.org\/10.1001\/jamacardio.2016.2839","journal-title":"JAMA Cardiol"},{"key":"10552_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari S, Casta\u00f1o A, Pozniakoff T et al (2013) 99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses. Circ Cardiovasc Imaging 6:195\u2013201. https:\/\/doi.org\/10.1161\/CIRCIMAGING.112.000132","journal-title":"Circ Cardiovasc Imaging"},{"key":"10552_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007558","volume":"14","author":"EB Schafer","year":"2021","unstructured":"Schafer EB, Tushak Z, Trankle CR et al (2021) False-Positive 99mTechnetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy. Circ Heart Fail 14:e007558. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007558","journal-title":"Circ Heart Fail"},{"key":"10552_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.007059","volume":"11","author":"ICY Chang","year":"2018","unstructured":"Chang ICY, Bois JP, Bois MC et al (2018) Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive 99mTechnetium\u2013Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis. Circ Cardiovasc Imaging 11:e007059. https:\/\/doi.org\/10.1161\/CIRCIMAGING.117.007059","journal-title":"Circ Cardiovasc Imaging"},{"key":"10552_CR30","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1007\/s12350-022-03059-5","volume":"29","author":"EJ Miller","year":"2022","unstructured":"Miller EJ, Campisi R, Shah NR et al (2022) Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement. J Nucl Cardiol 29:2748\u20132760. https:\/\/doi.org\/10.1007\/s12350-022-03059-5","journal-title":"J Nucl Cardiol"},{"key":"10552_CR31","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jcmg.2025.03.011","volume":"18","author":"RRS Packard","year":"2025","unstructured":"Packard RRS, Pelletier-Galarneau M, Malhotra S et al (2025) Established and Emerging Fluorine-18\u2013Labeled Cardiac PET Radiotracers. JACC Cardiovasc Imaging 18:815\u2013833. https:\/\/doi.org\/10.1016\/j.jcmg.2025.03.011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10552_CR32","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jcmg.2025.01.018","volume":"18","author":"DA Smiley","year":"2025","unstructured":"Smiley DA, Einstein AJ, O\u2019Gorman KJ et al (2025) Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography\/Computed Tomography. JACC Cardiovasc Imaging 18:799\u2013811. https:\/\/doi.org\/10.1016\/j.jcmg.2025.01.018","journal-title":"JACC Cardiovasc Imaging"},{"key":"10552_CR33","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","volume":"16","author":"OF Clerc","year":"2023","unstructured":"Clerc OF, Cuddy SAM, Robertson M et al (2023) Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I\u2013P5+14) Versus 18F-Florbetapir. JACC Cardiovasc Imaging 16:1419\u20131432. https:\/\/doi.org\/10.1016\/j.jcmg.2023.07.007","journal-title":"JACC Cardiovasc Imaging"},{"key":"10552_CR34","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10741-021-10098-6","volume":"27","author":"A Goyal","year":"2022","unstructured":"Goyal A, Lahan S, Dalia T et al (2022) Clinical comparison of V122I genotypic variant of transthyretin amyloid cardiomyopathy with wild-type and other hereditary variants: a systematic review. Heart Fail Rev 27:849\u2013856. https:\/\/doi.org\/10.1007\/s10741-021-10098-6","journal-title":"Heart Fail Rev"},{"key":"10552_CR35","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari A, Cappelli F, Nitsche C et al (2024) SGLT2 Inhibitor Therapy in Patients With Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol 83:2411\u20132422. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.429","journal-title":"J Am Coll Cardiol"},{"key":"10552_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","volume":"6","author":"S Giancaterino","year":"2020","unstructured":"Giancaterino S, Urey MA, Darden D, Hsu JC (2020) Management of Arrhythmias in Cardiac Amyloidosis. JACC Clin Electrophysiol 6:351\u2013361. https:\/\/doi.org\/10.1016\/j.jacep.2020.01.004","journal-title":"JACC Clin Electrophysiol"},{"key":"10552_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","volume":"133","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Sperry BW, Gabrovsek A et al (2020) Digoxin Use in Cardiac Amyloidosis. Am J Cardiol 133:134\u2013138. https:\/\/doi.org\/10.1016\/j.amjcard.2020.07.034","journal-title":"Am J Cardiol"},{"key":"10552_CR38","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/jce.14180","volume":"30","author":"E Donnellan","year":"2019","unstructured":"Donnellan E, Wazni OM, Saliba WI et al (2019) Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol 30:2427\u20132432. https:\/\/doi.org\/10.1111\/jce.14180","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10552_CR39","doi-asserted-by":"publisher","first-page":"S479","DOI":"10.1016\/j.healun.2019.01.1218","volume":"38","author":"K Maeda","year":"2019","unstructured":"Maeda K, Nasirov T, Yarlagadda V et al (2019) Novel Trans-Septal Left Atrial VAD Cannulation Technique for Hypertrophic\/Restrictive Cardiomyopathy. J Heart Lung Transplant 38:S479. https:\/\/doi.org\/10.1016\/j.healun.2019.01.1218","journal-title":"J Heart Lung Transplant"},{"key":"10552_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ahj.2021.02.016","volume":"236","author":"RO Ohiomoba","year":"2021","unstructured":"Ohiomoba RO, Youmans QR, Ezema A et al (2021) Cardiac transplantation outcomes in patients with amyloid cardiomyopathy. Am Heart J 236:13\u201321. https:\/\/doi.org\/10.1016\/j.ahj.2021.02.016","journal-title":"Am Heart J"},{"key":"10552_CR41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jaccao.2021.05.007","volume":"3","author":"RM Witteles","year":"2021","unstructured":"Witteles RM (2021) Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis. JACC CardioOncology 3:516\u2013521. https:\/\/doi.org\/10.1016\/j.jaccao.2021.05.007","journal-title":"JACC CardioOncology"},{"key":"10552_CR42","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.tcm.2025.03.002","volume":"35","author":"AA Girard","year":"2025","unstructured":"Girard AA, Asif T, Sperry BW (2025) Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions. Trends Cardiovasc Med 35:354\u2013362. https:\/\/doi.org\/10.1016\/j.tcm.2025.03.002","journal-title":"Trends Cardiovasc Med"},{"key":"10552_CR43","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jchf.2025.03.017","volume":"13","author":"JM Griffin","year":"2025","unstructured":"Griffin JM, Grodin JL, Ruberg FL et al (2025) Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy. JACC Heart Fail 13:685\u2013694. https:\/\/doi.org\/10.1016\/j.jchf.2025.03.017","journal-title":"JACC Heart Fail"},{"key":"10552_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott P, Drachman BM, Gottlieb SS et al (2022) Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy. Circ Heart Fail 15:e008193. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008193","journal-title":"Circ Heart Fail"},{"key":"10552_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","volume":"9","author":"C Rapezzi","year":"2021","unstructured":"Rapezzi C, Elliott P, Damy T et al (2021) Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC Heart Fail 9:115\u2013123. https:\/\/doi.org\/10.1016\/j.jchf.2020.09.011","journal-title":"JACC Heart Fail"},{"key":"10552_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamacardio.2023.4147","volume":"9","author":"SJ Shah","year":"2024","unstructured":"Shah SJ, Fine N, Garcia-Pavia P et al (2024) Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial. JAMA Cardiol 9:25\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2023.4147","journal-title":"JAMA Cardiol"},{"key":"10552_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10741-021-10143-4","volume":"27","author":"M Ibrahim","year":"2022","unstructured":"Ibrahim M, Saint Croix GR, Lacy S et al (2022) The use of diflunisal for transthyretin cardiac amyloidosis: a review. Heart Fail Rev 27:517\u2013524. https:\/\/doi.org\/10.1007\/s10741-021-10143-4","journal-title":"Heart Fail Rev"},{"key":"10552_CR48","doi-asserted-by":"publisher","unstructured":"Sant\u2019Anna R, Gallego P, Robinson LZ, et al (2016) Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun 7:10787. https:\/\/doi.org\/10.1038\/ncomms10787","DOI":"10.1038\/ncomms10787"},{"key":"10552_CR49","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1001\/jama.2023.18688","volume":"330","author":"T Coelho","year":"2023","unstructured":"Coelho T, Marques W Jr, Dasgupta NR et al (2023) Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA 330:1448\u20131458. https:\/\/doi.org\/10.1001\/jama.2023.18688","journal-title":"JAMA"},{"key":"10552_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med 379:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"10552_CR51","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1016\/j.febslet.2009.10.062","volume":"583","author":"N Ferreira","year":"2009","unstructured":"Ferreira N, Cardoso I, Domingues MR et al (2009) Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett 583:3569\u20133576. https:\/\/doi.org\/10.1016\/j.febslet.2009.10.062","journal-title":"FEBS Lett"},{"key":"10552_CR52","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","volume":"24","author":"J Wixner","year":"2017","unstructured":"Wixner J, Pilebro B, Lundgren H-E et al (2017) Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis. Amyloid 24:78\u201379. https:\/\/doi.org\/10.1080\/13506129.2016.1269739","journal-title":"Amyloid"},{"key":"10552_CR53","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"389","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P, Aus Dem Siepen F, Donal E et al (2023) Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med 389:239\u2013250. https:\/\/doi.org\/10.1056\/NEJMoa2303765","journal-title":"N Engl J Med"},{"issue":"ehac544","key":"10552_CR54","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/eurheartj\/ehac544.1767","volume":"43","author":"M Fontana","year":"2022","unstructured":"Fontana M, Buchholtz K, Engelmann MDM et al (2022) NNC6019\u20130001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial. Eur Heart J 43(ehac544):1767. https:\/\/doi.org\/10.1093\/eurheartj\/ehac544.1767","journal-title":"Eur Heart J"},{"key":"10552_CR55","unstructured":"Prothena Biosciences Limited (2020) A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis. clinicaltrials.gov"},{"key":"10552_CR56","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek M, Chylinski K, Fonfara I et al (2012) A Programmable Dual-RNA\u2013Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science 337:816\u2013821. https:\/\/doi.org\/10.1126\/science.1225829","journal-title":"Science"},{"key":"10552_CR57","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1056\/NEJMoa2107454","volume":"385","author":"JD Gillmore","year":"2021","unstructured":"Gillmore JD, Gane E, Taubel J et al (2021) CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med 385:493\u2013502. https:\/\/doi.org\/10.1056\/NEJMoa2107454","journal-title":"N Engl J Med"},{"key":"10552_CR58","doi-asserted-by":"publisher","unstructured":"Fontana M, Solomon SD, Kachadourian J, et al CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N Engl J Med 0: https:\/\/doi.org\/10.1056\/NEJMoa2412309","DOI":"10.1056\/NEJMoa2412309"},{"key":"10552_CR59","unstructured":"Intellia Therapeutics (2024) MAGNITUDE: a Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM). clinicaltrials.gov"},{"key":"10552_CR60","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P et al (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98:1442\u20131448. https:\/\/doi.org\/10.1136\/heartjnl-2012-302353","journal-title":"Heart"},{"key":"10552_CR61","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/ejhf.2504","volume":"24","author":"M Merlo","year":"2022","unstructured":"Merlo M, Pagura L, Porcari A et al (2022) Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey. Eur J Heart Fail 24:1377\u20131386. https:\/\/doi.org\/10.1002\/ejhf.2504","journal-title":"Eur J Heart Fail"},{"key":"10552_CR62","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCULATIONAHA.115.016567","volume":"132","author":"M Fontana","year":"2015","unstructured":"Fontana M, Pica S, Reant P et al (2015) Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation 132:1570\u20131579. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016567","journal-title":"Circulation"},{"key":"10552_CR63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12872-016-0311-6","volume":"16","author":"L Zhao","year":"2016","unstructured":"Zhao L, Tian Z, Fang Q (2016) Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovasc Disord 16:129. https:\/\/doi.org\/10.1186\/s12872-016-0311-6","journal-title":"BMC Cardiovasc Disord"},{"key":"10552_CR64","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","volume":"7","author":"M Fontana","year":"2014","unstructured":"Fontana M, Banypersad SM, Treibel TA et al (2014) Native T1 Mapping in Transthyretin Amyloidosis. JACC Cardiovasc Imaging 7:157\u2013165. https:\/\/doi.org\/10.1016\/j.jcmg.2013.10.008","journal-title":"JACC Cardiovasc Imaging"},{"key":"10552_CR65","doi-asserted-by":"publisher","unstructured":"Mongeon F-P, Jerosch -Herold Michael, Coelho -Filho Ot\u00e1vio Rizzi, et al (2012) Quantification of Extracellular Matrix Expansion by CMR in Infiltrative Heart Disease. JACC Cardiovasc Imaging 5:897\u2013907. https:\/\/doi.org\/10.1016\/j.jcmg.2012.04.006","DOI":"10.1016\/j.jcmg.2012.04.006"},{"key":"10552_CR66","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jcmg.2013.09.019","volume":"7","author":"JA White","year":"2014","unstructured":"White JA, Kim HW, Shah D et al (2014) CMR Imaging With Rapid Visual T1 Assessment Predicts Mortality in Patients Suspected of Cardiac Amyloidosis. JACC Cardiovasc Imaging 7:143\u2013156. https:\/\/doi.org\/10.1016\/j.jcmg.2013.09.019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10552_CR67","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","volume":"7","author":"DR Davies","year":"2022","unstructured":"Davies DR, Redfield MM, Scott CG et al (2022) A Simple Score to Identify Increased Risk of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. JAMA Cardiol 7:1036\u20131044. https:\/\/doi.org\/10.1001\/jamacardio.2022.1781","journal-title":"JAMA Cardiol"},{"key":"10552_CR68","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","volume":"13","author":"M Boldrini","year":"2020","unstructured":"Boldrini M, Cappelli F, Chacko L et al (2020) Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging 13:909\u2013920. https:\/\/doi.org\/10.1016\/j.jcmg.2019.10.011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10552_CR69","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jcmg.2023.05.002","volume":"16","author":"X Arana-Achaga","year":"2023","unstructured":"Arana-Achaga X, Goena-Vives C, Villanueva-Benito I et al (2023) Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo. JACC Cardiovasc Imaging 16:1567\u20131580. https:\/\/doi.org\/10.1016\/j.jcmg.2023.05.002","journal-title":"JACC Cardiovasc Imaging"},{"key":"10552_CR70","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","volume":"96","author":"M Grogan","year":"2021","unstructured":"Grogan M, Lopez-Jimenez F, Cohen-Shelly M et al (2021) Artificial Intelligence-Enhanced Electrocardiogram for the Early Detection of Cardiac Amyloidosis. Mayo Clin Proc 96:2768\u20132778. https:\/\/doi.org\/10.1016\/j.mayocp.2021.04.023","journal-title":"Mayo Clin Proc"},{"key":"10552_CR71","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.118.005289","volume":"12","author":"GH Tison","year":"2019","unstructured":"Tison GH, Zhang J, Delling FN, Deo RC (2019) Automated and Interpretable Patient ECG Profiles for Disease Detection, Tracking, and Discovery. Circ Cardiovasc Qual Outcomes 12:e005289. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.118.005289","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10552_CR72","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/s41467-021-22877-8","volume":"12","author":"S Goto","year":"2021","unstructured":"Goto S, Mahara K, Beussink-Nelson L et al (2021) Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms. Nat Commun 12:2726. https:\/\/doi.org\/10.1038\/s41467-021-22877-8","journal-title":"Nat Commun"},{"key":"10552_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2022.100013","volume":"13","author":"AY Wang","year":"2022","unstructured":"Wang AY, Sharma V, Saini H et al (2022) Machine Learning Quantification of Amyloid Deposits in Histological Images of Ligamentum Flavum. J Pathol Inform 13:100013. https:\/\/doi.org\/10.1016\/j.jpi.2022.100013","journal-title":"J Pathol Inform"},{"key":"10552_CR74","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12968-020-00690-4","volume":"22","author":"N Martini","year":"2020","unstructured":"Martini N, Aimo A, Barison A et al (2020) Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 22:84. https:\/\/doi.org\/10.1186\/s12968-020-00690-4","journal-title":"J Cardiovasc Magn Reson"},{"key":"10552_CR75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13550-022-00897-9","volume":"12","author":"H-L Halme","year":"2022","unstructured":"Halme H-L, Ihalainen T, Suomalainen O et al (2022) Convolutional neural networks for detection of transthyretin amyloidosis in 2D scintigraphy images. EJNMMI Res 12:27. https:\/\/doi.org\/10.1186\/s13550-022-00897-9","journal-title":"EJNMMI Res"},{"key":"10552_CR76","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jcmg.2023.01.014","volume":"16","author":"M-A Delbarre","year":"2023","unstructured":"Delbarre M-A, Girardon F, Roquette L et al (2023) Deep Learning on Bone Scintigraphy to Detect Abnormal Cardiac Uptake at Risk of Cardiac Amyloidosis. JACC Cardiovasc Imaging 16:1085\u20131095. https:\/\/doi.org\/10.1016\/j.jcmg.2023.01.014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10552_CR77","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/jcdd11040118","volume":"11","author":"MA Kamel","year":"2024","unstructured":"Kamel MA, Abbas MT, Kanaan CN et al (2024) How Artificial Intelligence Can Enhance the Diagnosis of Cardiac Amyloidosis: A Review of Recent Advances and Challenges. J Cardiovasc Dev Dis 11:118. https:\/\/doi.org\/10.3390\/jcdd11040118","journal-title":"J Cardiovasc Dev Dis"},{"key":"10552_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100612","volume":"2","author":"DM Harmon","year":"2023","unstructured":"Harmon DM, Mangold K, Baez SA et al (2023) Postdevelopment Performance and Validation of the Artificial Intelligence-Enhanced Electrocardiogram for Detection of Cardiac Amyloidosis. JACC Adv 2:100612. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100612","journal-title":"JACC Adv"},{"key":"10552_CR79","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","volume":"146","author":"A Ioannou","year":"2022","unstructured":"Ioannou A, Patel RK, Razvi Y et al (2022) Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years. Circulation 146:1657\u20131670. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060852","journal-title":"Circulation"},{"key":"10552_CR80","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamacardio.2024.5221","volume":"10","author":"A Porcari","year":"2025","unstructured":"Porcari A, Razvi Y, Cappelli F et al (2025) Clinical Phenotype and Prognosis of Asymptomatic Patients With Transthyretin Cardiac Amyloid Infiltration. JAMA Cardiol 10:437\u2013445. https:\/\/doi.org\/10.1001\/jamacardio.2024.5221","journal-title":"JAMA Cardiol"},{"key":"10552_CR81","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13023-024-03198-7","volume":"19","author":"TN Qarni","year":"2024","unstructured":"Qarni TN, Jones FJS, Drachman B et al (2024) Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study. Orphanet J Rare Dis 19:191. https:\/\/doi.org\/10.1186\/s13023-024-03198-7","journal-title":"Orphanet J Rare Dis"},{"key":"10552_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2024.102414","volume":"29","author":"NM Fine","year":"2024","unstructured":"Fine NM, Witteles RM (2024) Drug Development for Transthyretin Amyloidosis. JACC Case Rep 29:102414. https:\/\/doi.org\/10.1016\/j.jaccas.2024.102414","journal-title":"JACC Case Rep"},{"key":"10552_CR83","doi-asserted-by":"publisher","unstructured":"Lau ATC, DiDomenico RJ, Kim K (2024) Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States. Int J Cardiol 398:. https:\/\/doi.org\/10.1016\/j.ijcard.2023.131598","DOI":"10.1016\/j.ijcard.2023.131598"},{"key":"10552_CR84","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV et al (2023) 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. J Am Coll Cardiol 81:1076\u20131126. https:\/\/doi.org\/10.1016\/j.jacc.2022.11.022","journal-title":"J Am Coll Cardiol"},{"key":"10552_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101784","volume":"4","author":"NK Bart","year":"2025","unstructured":"Bart NK, Bianchi G, Cuddy SAM et al (2025) Cardiac Amyloidosis in Older Adults With a Focus on Frailty. JACC Adv 4:101784. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101784","journal-title":"JACC Adv"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10552-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-025-10552-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-025-10552-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T20:04:41Z","timestamp":1763150681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-025-10552-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":85,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10552"],"URL":"https:\/\/doi.org\/10.1007\/s10741-025-10552-9","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"12 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JPC reports consulting income from Pfizer and AstraZeneca. AD, LD, EM, UJ, and YR have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}